Enobosarm inhibits breast cancer development: Study
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Enobosarm is a selective androgen receptor targeting agonist developed by Veru Inc. The U.S. Food and Drug Administration has granted a fast-track designation to the experimental drug for the treatment of patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
The Phase 2, multi-site international study led by Dr Beth Overmoyer of the Dana-Farber Cancer Institute of Boston, the United States, evaluated the efficacy and safety of enobosarm in 136 postmenopausal women with locally advanced or metastatic ER-positive, HER2-negative breast cancer.
Enobosarm was found to have anti-tumor effects and was well tolerated with no significant impact on quality of life, according to reports of HealthDay News on Thursday.
This is the first approach that involves a non-estrogen receptor hormonal therapy to show clinical improvements in ER-positive breast cancer.
In the clinical study, patients were randomized to 9 mg or 18 mg of oral enobosarm daily over an average of seven and a half months. The primary endpoint was the clinical benefit rate at six months.
The drug was found to show significant clinical benefits, including anti-cancer activity.
The clinical benefit rate was 32 percent in the 9-mg group compared with 29 percent in the 18-mg group.
Average progression-free survival (PFS) was 5.6 months in the 9mg-dose group and 4.2 months in the higher-dose group.
Eight percent of the 9-mg group had drug-related adverse events, such as liver damage and fatigue, with 16 percent in the 18-mg group.
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- “이강인 국가대표 자격 영구 박탈해달라”…대한체육회 징계 민원 접수 - 매일경제
- 10대 소녀팬 몰고 다녔던 ‘고교야구 전설’…우석대 총장 됐다 - 매일경제
- [속보] 대한축구협회, 클린스만 대표팀 감독에게 경질 통보 - 매일경제
- 삼성전자 어쩌나...7년 반만에 ‘이 기업’에 아시아 시총 추월당했다 - 매일경제
- “불매, 죽을 때까지 안사먹는다”…이강인 모델 쓴 기업도 날벼락 - 매일경제
- ‘슈퍼을’ 회사 5곳이 전세계에서 떵떵…“부르는 게 값” 이것 뭐길래 - 매일경제
- 오늘의 운세 2024년 2월 16일 金(음력 1월 7일) - 매일경제
- 빚내서 산 집 결국 반토막까지…노도강 영끌족의 눈물 - 매일경제
- “항공권이 가장 저렴한 때는”…알고 떠나면 더 좋은 여행 꿀팁 [여책저책] - 매일경제
- “잘할 거니까, 저만 잘하면 돼요” 맞대결 앞둔 김하성과 이정후의 이구동성 [MK현장] - MK스포츠